CBC with Differential: Drugs That Distort This Test

What a CBC with Differential Actually Measures

A CBC with differential is the single most ordered blood test in clinical medicine. It quantifies three cell lineages produced by bone marrow: red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes).

Red Blood Cell Parameters

The red cell portion reports hemoglobin concentration, hematocrit (the percentage of blood volume occupied by red cells), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and red cell distribution width (RDW). These values detect anemia, polycythemia, and nutritional deficiencies [1]. A hemoglobin below 13.5 g/dL in adult males or below 12.0 g/dL in adult females meets the WHO definition of anemia.

White Blood Cell Differential

The "differential" splits total WBC into five subtypes: neutrophils (40 to 70% of total WBC), lymphocytes (20 to 40%), monocytes (2 to 8%), eosinophils (1 to 4%), and basophils (0 to 1%). Automated hematology analyzers classify cells by size, nuclear complexity, and granularity. A manual smear review is triggered when flagged abnormalities appear [2].

Platelet Count and Indices

Platelet counts below 150,000/mcL indicate thrombocytopenia; counts above 400,000/mcL indicate thrombocytosis. Mean platelet volume (MPV) reflects platelet age: younger platelets are larger. Drug-induced thrombocytopenia is one of the most clinically dangerous CBC distortions because it can cause spontaneous bleeding at counts below 20,000/mcL [3].

Drugs That Raise Red Blood Cell Counts and Hemoglobin

Several medications stimulate erythropoiesis or concentrate red cell mass, pushing hemoglobin and hematocrit above the reference range. This is not always pathological, but hematocrit above 54% raises venous thromboembolism risk significantly [4].

Testosterone and Anabolic Steroids

Testosterone replacement therapy (TRT) is the most common cause of drug-induced erythrocytosis in the outpatient setting. The Endocrine Society 2018 Clinical Practice Guideline recommends checking hematocrit at baseline, 3 to 6 months after starting TRT, and annually thereafter [5]. Testosterone stimulates erythropoietin production and suppresses hepcidin, increasing iron absorption. In the Testosterone Trials (TTrials, N=790), men receiving transdermal testosterone saw mean hemoglobin rise by 1.0 g/dL over 12 months [6]. Hematocrit above 54% requires dose reduction, phlebotomy, or a switch to a shorter-acting ester.

Erythropoiesis-Stimulating Agents

Epoetin alfa and darbepoetin alfa directly stimulate red cell production. The FDA black-box warning mandates hemoglobin targets of 10 to 12 g/dL in chronic kidney disease, because targeting higher levels increased cardiovascular events in the CHOIR trial (N=1,432) [7].

Other Red-Cell-Raising Drugs

Cobalt supplements (sometimes used illicitly for endurance enhancement) mimic hypoxia and drive EPO production. Recombinant growth hormone may raise hemoglobin modestly (0.3 to 0.5 g/dL) through IGF-1-mediated erythropoiesis [8].

Drugs That Lower Red Blood Cell Counts (Drug-Induced Anemia)

Drug-induced anemia has at least four mechanisms: bone marrow suppression, hemolysis, impaired nutrient absorption, and chronic blood loss.

Chemotherapy and Immunosuppressants

Cytotoxic agents (cyclophosphamide, methotrexate, doxorubicin) suppress all marrow lineages. Methotrexate-induced pancytopenia occurs even at low rheumatologic doses (7.5 to 25 mg/week) in patients with renal impairment or folate deficiency [9]. Mycophenolate mofetil causes anemia in 25 to 40% of transplant recipients.

Proton Pump Inhibitors and Metformin

Long-term PPI use impairs iron and vitamin B12 absorption. A 2019 meta-analysis (N=83,519) found PPI use for more than two years raised B12 deficiency risk by 65% (OR 1.65, 95% CI 1.42 to 1.93) [10]. Metformin similarly reduces B12 absorption in the terminal ileum. The American Diabetes Association 2024 Standards of Care recommends periodic B12 monitoring in metformin-treated patients [11].

Hemolysis-Inducing Medications

Ribavirin, dapsone, methyldopa, and high-dose penicillin can trigger hemolytic anemia through oxidative stress or immune-mediated mechanisms. In patients with G6PD deficiency, nitrofurantoin, primaquine, and sulfonamides precipitate acute hemolytic crises with hemoglobin drops of 3 to 5 g/dL within days [12].

Drugs That Raise White Blood Cell Counts

A WBC above 11,000/mcL is leukocytosis. Drug-induced leukocytosis can mimic infection or myeloproliferative disease and trigger unnecessary imaging, bone marrow biopsies, and antibiotic prescriptions.

Corticosteroids

This is the single most frequent drug cause of an elevated WBC. Prednisone at doses as low as 10 mg/day raises the total WBC by 2,000 to 5,000 cells/mcL within 4 to 6 hours of a dose. The mechanism is demargination: steroids release neutrophils from blood vessel walls into circulating blood and simultaneously block neutrophil migration out of the bloodstream [13]. The differential shows isolated neutrophilia with normal or low lymphocytes. This "pseudo-leukocytosis" resolves 24 to 48 hours after the last dose.

Lithium

Lithium carbonate raises total WBC by 2,000 to 4,000 cells/mcL in a dose-dependent fashion, primarily through increased granulocyte colony-stimulating factor (G-CSF) release. A patient on lithium 900 mg/day may show WBC of 13,000 to 15,000/mcL as a stable new baseline [14]. This effect is so predictable that lithium was historically used to treat drug-induced neutropenia before recombinant G-CSF became available.

Beta-2 Agonists and Epinephrine

Albuterol, formoterol, and injectable epinephrine cause acute leukocytosis through catecholamine-mediated demargination. A single albuterol nebulizer treatment can raise WBC by 1,500 to 3,000 cells/mcL within 30 minutes [15].

Drugs That Lower White Blood Cell Counts (Drug-Induced Neutropenia and Leukopenia)

Neutropenia (absolute neutrophil count, ANC, below 1,500/mcL) carries infection risk. Severe neutropenia (ANC <500/mcL) is a medical emergency.

Clozapine

Clozapine carries the most stringent CBC monitoring requirement of any outpatient medication. The FDA-mandated REMS program requires weekly CBC for the first 6 months, biweekly for months 7 to 12, and monthly thereafter [16]. Clozapine-induced agranulocytosis occurs in approximately 0.8% of patients, typically within the first 18 weeks. ANC below 1,000/mcL requires immediate discontinuation.

Antithyroid Drugs

Methimazole and propylthiouracil cause agranulocytosis in 0.1 to 0.5% of users. The American Thyroid Association guideline states that patients must be warned to report sore throat or fever immediately, as agranulocytosis onset is typically abrupt rather than gradual [17]. Baseline CBC is recommended before starting either drug, with repeat testing when symptoms arise.

Chemotherapy, Carbimazole, and Other Agents

Beyond cytotoxic chemotherapy, several commonly prescribed drugs cause neutropenia: carbamazepine (1 to 2% of patients), sulfasalazine, trimethoprim-sulfamethoxazole, vancomycin, and ganciclovir. ACE inhibitors cause neutropenia rarely (about 0.1%) but more frequently in patients with renal impairment or collagen vascular disease [18].

Drugs That Affect Platelet Counts

Heparin-Induced Thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is the most dangerous drug-platelet interaction. Type II HIT involves antibodies against platelet factor 4 (PF4)-heparin complexes and occurs in 1 to 5% of patients receiving unfractionated heparin for more than 5 days [19]. Platelet counts typically drop 50% or more from baseline between days 5 and 14. Paradoxically, HIT causes thrombosis rather than bleeding. The "4Ts score" helps differentiate HIT from other causes of inpatient thrombocytopenia.

Valproic Acid

Valproate causes dose-dependent thrombocytopenia in 5 to 40% of patients, with higher rates at trough levels above 100 mcg/mL. Platelet counts usually remain above 100,000/mcL but may require dose reduction [20].

Linezolid and Other Antibiotics

Linezolid suppresses megakaryopoiesis and causes thrombocytopenia in 2.4% of patients treated for 10 to 14 days but in up to 30 to 50% of patients treated beyond 14 days. The mechanism is mitochondrial toxicity in megakaryocyte precursors [21].

Drugs That Raise Platelet Counts

Iron supplementation in iron-deficient patients with reactive thrombocytopenia may initially raise platelets further before counts normalize. Romiplostim and eltrombopag (TPO receptor agonists) are designed to raise platelet counts in immune thrombocytopenia and carry a risk of rebound thrombocytopenia on discontinuation [22].

Hormonal Therapies and the CBC: TRT, HRT, and GLP-1 Agonists

Testosterone Effects on All Three Lineages

Testosterone raises hemoglobin and hematocrit (discussed above), may mildly raise WBC through androgen receptor signaling on myeloid progenitors, and has no consistent effect on platelets. The Endocrine Society recommends withholding TRT if baseline hematocrit exceeds 48% in high-cardiovascular-risk patients and stopping therapy if hematocrit rises above 54% [5].

Dr. Shalender Bhasin, principal investigator of the TTrials, has stated: "Polycythemia is the most common adverse effect of testosterone therapy and requires systematic hematocrit monitoring, particularly in older men and those on injectable formulations" [6].

Estrogen and Progesterone (HRT)

Oral estrogen (but not transdermal) raises C-reactive protein and may mildly depress hemoglobin through hemodilution effects. Combined HRT has no clinically meaningful effect on WBC differential in most patients. A Women's Health Initiative substudy found no significant CBC parameter changes attributable to conjugated equine estrogen plus medroxyprogesterone over 5.2 years [23].

GLP-1 Receptor Agonists

Semaglutide and tirzepatide have not shown clinically significant CBC distortions in major trials. In STEP-1 (N=1,961), semaglutide 2.4 mg did not alter WBC, hemoglobin, or platelet counts versus placebo at 68 weeks [24]. Rare post-marketing reports describe mild eosinophilia with GLP-1 agonists, possibly linked to injection-site hypersensitivity [25].

How to Interpret a Drug-Distorted CBC

Step 1: Timeline the Change

The single most useful question: "Did this abnormality appear after a new drug was started or a dose was changed?" Drug-induced CBC shifts follow predictable timelines. Corticosteroid leukocytosis starts within hours. HIT thrombocytopenia peaks at days 5 to 14. TRT erythrocytosis builds over 3 to 6 months. Methotrexate pancytopenia can appear weeks to months after initiation.

Step 2: Check the Differential Pattern

Drug-induced neutrophilia (steroids, lithium) looks different from infection-driven neutrophilia. Steroids produce a "left shift" on paper, but band forms remain low. Infectious leukocytosis drives both total WBC and immature granulocytes (bands >6%).

Step 3: Repeat Before Reacting

The AACE 2020 Clinical Practice Guideline for thyroid disease recommends confirming an abnormal CBC before ordering expensive downstream tests [26]. A single mildly abnormal value in a stable patient on a known CBC-altering drug almost never warrants bone marrow biopsy.

Practical Drug-by-Drug Quick Reference Table

| Drug / Class | CBC Parameter Affected | Direction | Magnitude | Onset | |---|---|---|---|---| | Testosterone (TRT) | Hemoglobin, hematocrit | Up | Hgb +1.0 g/dL avg | 3 to 6 months | | Prednisone 10+ mg | WBC (neutrophils) | Up | +2,000 to 5,000/mcL | 4 to 6 hours | | Lithium | WBC (neutrophils) | Up | +2,000 to 4,000/mcL | 1 to 2 weeks | | Clozapine | WBC (neutrophils) | Down | ANC may fall <500 | 6 to 18 weeks | | Methimazole | WBC (neutrophils) | Down | Agranulocytosis 0.1 to 0.5% | Weeks to months | | Metformin | Hemoglobin (via B12) | Down | Mild, gradual | Months to years | | Heparin (UFH) | Platelets | Down | 50%+ drop | Days 5 to 14 | | Valproic acid | Platelets | Down | Dose-dependent | Weeks | | Epoetin alfa | Hemoglobin | Up | Target 10 to 12 g/dL | 2 to 6 weeks | | Chemotherapy | All lineages | Down | Variable, may be severe | 7 to 14 days (nadir) |

When to Recheck and When to Escalate

Mild, expected drug-induced shifts (TRT-related hematocrit of 50%, lithium-related WBC of 13,000) require monitoring at the intervals specified by prescribing guidelines, not urgent intervention. Recheck in 4 to 6 weeks to confirm stability.

Escalate immediately if: ANC falls below 1,000/mcL on any drug, platelet count drops below 50,000/mcL without a clear drug cause, hemoglobin drops more than 2 g/dL acutely, or new blast cells appear on differential. These findings warrant same-day hematology consultation regardless of medication history.

Patients on TRT should have a CBC drawn 3 to 6 months after each dose adjustment and at least annually once stable, per the Endocrine Society 2018 guideline [5]. Patients on clozapine follow the REMS schedule without exception [16].